Meta Pixel

News and Announcements

GDTC Welcomes Increased Investment from MTAQ

  • Published February 16, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Green Distillation Technologies (GDTC), who has developed a proprietary process to convert End of Life Tyres (ELT) into the saleable commodities of carbon, oil and steel, profitably, with no waste and a negative carbon footprint, have recently revised their capital raising opportunity and welcomed MTAQ – the Motor Trades Association of Queensland in committing a further $1.5m in the current raise of $5m at a discounted equity price. 

In addition to the Australian Government legislation, which bans the export of whole baled tyres, it was announced in January 2022 that the Indian Government plans to prohibit the import of waste tyres destined for pyrolysis plants. This is a significant initiative that will affect the international waste tyre market but it will also further add to the volumes that will require processing here in Australia. This is a real positive for GDTC.

The capital will be used to expand their Warren plant to 50% capacity and be able to operate 24/7 and generate revenues from tyre disposal fees, and the off-take products of oil, carbon and steel. A further raise via IPO will be held in 2023. 

Further information on the revised offer can be obtained in the CRIISPTM deal room.

Learn more about the GDT process by watching this video here

Register Interest

About Green Distillation Technologies

Green Distillation Technologies (GDT) is an Australian company that has developed and proven a proprietary process that converts end of life tyres into 3 saleable commodities of carbon, oil and steel. In Australia 26 million waste tyres are generated each year and if discarded will take at least 300 years to biodegrade. In 2020 Tyre Stewardship Australia estimated that 71% of ‘on road’ waste tyres were exported. In December 2021, the Federal Government ban on exporting waste tyres will see the doubling of volumes to be processed in Australia.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now